3 results
To evaluate patient related outcomes mainly quality of life and treatment satisfaction. Side effects and therapy adherence were also evaluated because these can interfere with quality of life and treatment satisfaction.
Primary objective: to determine the biological activityof Hespecta that is able to induce HPV16 E6-specific T-cell immunity within a proposed dose escalation of 1, 5, 20 or 50 µg/peptide - conjugate in patients treated for HPV16+ OSCC.Secondary…
To analyze the molecular effects and dose-response relationship of HBOT in patients with moderate-to-severe UC refractory to medical therapy, more specifically to evaluate: - Clinical, endoscopic, histological and ultrasonographic disease activity-…